Furthermore, the fact that AB248-induced signaling is not restricted to the tumor site may be advantageous, as FTY720 treatment suggested that newly infiltrating cells from the periphery contribute to the antitumor activity of CD8-mIL2 (Supplementary Fig. S4C and S4D), consistent with other immunotherapies (68). This evidence concerns the gene CD8A and neoplasm.